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The role of the Dentist and, in particular, the role of the 
Oral Medicine specialist as a front-line sentinel in the 
interception of oral cancer has been consolidated since 
long time. However, over the last decade there have not 
been any recent developed diagnostic strategies that 
can facilitate neither a more precise general framework 
nor a definition of the degree of local and systemic 
involvement, as well as the type of behavior. 
Head and neck cancer (HNC), is the sixth most common 
type of cancer in the world and accounts for 
approximately 550,000 cases per year [1]. HNC 
encompasses a wide range of malignancies arising from 
the head and neck region, including the oral district, the 
oropharynx, and larynx. More than 90% of HNCs are 
squamous cell carcinomas (SCCs), which frequently 
develop from the mucous surfaces of the mouth [2]. 
Oral squamous cell carcinoma (OSCC), characterized 
by differentiation and a tendency to metastatic lymph 
node spread [3], is the sixth most common cancer 
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worldwide with over 200,000 new diagnoses every year 
globally. 
From a topographical point of view, it can be divided into 
three main sub-sites: buccal mucosal SCC (BMSCC), 
tongue SCC (TSCC) and labial SCC (LSCC) [4], [5]. The 
morbidity and mortality rates in males are 6.6/100,000 
and 3.1/100,000respectively, while in females the same 
percentages are 2.9/100,000 and 1.4/100,000 [6]. 
Furthermore, the incidence of OSCC is increasing 
among young white individuals aged 18 to 44 years, 
particularly among white women [7]. Due to the 
frequency of exposure to risk factors in the population, 
the low cure rate and high mortality, OSCC represents a 
global public health problem with a large individual and 
socioeconomic burden. 
This type of cancer is very common in South-Central 
Asia, being the most common cancer in men in high-risk 
countries [8]. It is reported in the literature that in South 
Asian countries such as India, Sri Lanka, Pakistan and 
Bangladesh a quarter of new cancer cases are 
diagnosed as OSCC, being the third most common type 
of cancer [9]. Many risk factors have been linked to the 
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development of OSCC, most notably Rodriguez et al. 
showed in their study that, in terms of risk attributable to 
the population, tobacco smoking accounted for 77% of 
all oral and pharyngeal cancers, alcohol consumption for 
52% and the combination of the two for 83%. As for the 
diet, the risks attributable to the population estimated 
were 52% for the low vegetable content, 12% for the low 
fruit content, 26% for the low β-carotene intake. The 
combination of tobacco, alcohol and low vegetable 
consumption accounted for 85% of all cases in this 
population [10]. 
When diagnosed at an advanced stage, treatment of 
OSCC involves particularly invasive procedures since, in 
most cases, the disease is fatal due to the high rate of 
early metastasis to regional cervical lymph nodes; 
treating these patients is a challenge for clinicians [11]. 
Early-stage OSCC, however, has a favorable prognosis 
and requires less aggressive treatment [12]. The 5-year 
overall survival rate for OSCC is less than 50% and has 
improved only modestly over the past 2 decades despite 
the dramatic improvement in treatment modalities [13].  
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Although tumor-node-metastasis (TNM) based on 
neoplastic staging is routinely used to predict tumor 
behavior and, consequently, to inform about the choice 
of treatment strategies of OSCC, patients with the same 
TNM stages may have non-overlapping clinical 
evolutions and a significantly different survival time [14]. 
These inconsistencies require the development of new 
and more in-depth prognostic techniques and tools that 
can be used in the management of OSCC. 
For these reasons, the search for biomarkers which 
could be used for diagnosis and prognosis represents a 
growing hope to provide doctors with new tools for the 
treatment of the disease. 
The term Biomarker refers to an indicator, which can be 
measured, and which can be linked to a specific 
condition. Several definitions have been proposed for 
biomarkers in the literature. The Biomarkers Definition 
Working Group (formed by the US National Institutes of 
Health (NIH) and the US Food and Drug Administration 
(FDA), academia and industry) defined the biomarker as 
"a feature that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic 
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processes or pharmacological responses to a 
therapeutic intervention”[15]. With the advent of the 
genomic era, in April 2008, the FDA published - in one of 
its documents - "Guidance for Industry" specific 
definition of a genomic biomarker as "a measurable 
characteristic of DNA and/or RNA that is an indicator of 
normal biological processes, pathogenic processes, 
and/or response to therapeutic or other interventions" 
[16]. More recently, Anderson and Kodukulahave 
provided some definitions of different types of 
biomarkers (e.g., surrogate, clinical, diagnostic, 
prognostic, predictive, pharmacodynamic, efficacy, and 
toxicity/safety endpoints in their review of role of 
biomarkers in pharmacology and drug discovery) [17]. 
All these definitions specify the requirements that a 
biomarker must possess, the different existingtypes, 
their potential role in the diagnosis and progression of 
the disease or in the control of the therapeutic response 
and their usefulness for the evaluation of new chemical 
entities as potential guiding therapies [18]. 
Recently, due to their relative stability and abundance, 
non-coding RNAs have emerged as useful biomarkers in 
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tumors, due to their diverse roles in many biological 
processes, from carcinogenesis, cell differentiation and 
metastasis. These could provide physicians with diverse 
information, from the biology of tumors to their 
correlation to clinical outcomes [19]. 
In this perspective, oral carcinogenesis is a multi-step 
process involving the development and progression of 
OSCC from normal mucosa or premalignant lesions [20]. 
This process has led not only to irreversible genetic 
changes in the DNA sequence, but also to epigenetic 
events orchestrated by key regulatory molecules [21], 
[22]. Recently, the role of non-coding RNAs, including 
long and microRNAs, has acquired considerable 
importance in the epigenetics of carcinogenesis 
treatment for this type of disease must challenge the 
significant discrepancies in therapeutic response in 
individuals. Thus, the discovery and validation of new 
biomarkers such as non-coding RNAs will contribute to 
more accurate treatment monitoring and the 
development of personalized therapies, both with a 
direct impact on patients' quality of life [23]. 
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1.1 Squamous cell carcinoma of the oral cavity 
(OSCC) causative factors 
 
More than 90% of malignant neoplasms of the upper 
aerodigestive tract are represented by squamous cell 
carcinomas (SCC) with common causative factors [24]. 
The keratinocyte of the oral mucosa represents the 
cellular structure from which this type of neoplasm 
originates. Moreover, a spontaneous DNA mutation in 
this cellular structure - often associated with the co-
presence of physical, chemical or microbial mutagenic 
agents - represents the causal biological factor. 
Following these initial genomic alterations, oral 
keratinocytes can move towards a premalignant or 
potentially malignant profile and can associate with an 
altered cell proliferation, up to a condition of cellular 
autonomy and complete release from the cell cycle 
control systems, with subsequent invasion of frankly 
malignant cells through the epithelial basement 
membrane and their subsequent metastatic spread to 
the lymph node and/or systemic level. 
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The main agents associated with the genesis of an oral 
keratinocyte DNA mutation are represented by lifestyle 
related factors, although environmental and genetic 
predisposition aspects may represent additional risk 
factors related to the onset of the tumor [25]. 
As for the determining factors related to lifestyle, the role 
of tobacco use, and alcohol consumption certainly 
represents the most associatedelements with neoplastic 
onset, immediately followed by betel chewing and a diet 
associated with a high intake of fats and sugars. 
According to a study conducted by Petti, 25% of oral 
cancers are attributable to tobacco consumption 
(smoking and/or chewing), 7-19% to alcohol 
consumption, 10-15% to micronutrient deficiency in diets 
with reduced intake of fruit and vegetables, and more 
than 50% to the chewing of betel, even if referable only 
in geographic regions with a high prevalence of chewing 
[26]. 
With regard to environmental factors, viral infections, 
and in particular that of Human Papilloma Virus (HPV), 
find dissimilar results in investigations concerning its 
possible intervention in oral oncogenesis [27], while its 
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role in the genesis of oropharyngeal carcinomas HPV-
related oncogenicity has been widely documented in the 
gynecological field where the virus is considered the 
main causative agent of cervical cancer [28]. The high-
risk viral genotypes identified so far are 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70 and the data 
relating to the scientific literature are constantly evolving 
[29]. After contagion, the life cycle of the virus is strictly 
dependent on the differentiation process of the 
keratinocyte, the target cell of the infection. It begins with 
the entry of the virus into the cells of the germinative 
layer of the epithelium, equipped with the specific α6 
integrin receptor and marked proliferative activity, 
previously exposed to microabrasions of the epithelial 
lining. This aspect explains the particular susceptibility of 
some epithelial districts in which the basal and 
parabasal cells are constantly exposed to the 
environment (oropharyngeal mucosa at the tonsillar 
crypts, oropharynx). 
Other types of infectious processes such as candidiasis 
and syphilis have been considered as possible authors 
in the onset of cancer and more recently in the 
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microbiological field the possible role of the oral bacterial 
flora has also been feared. Indeed, the discovery of a 
greater incidence of areas of dysplasia and esophageal 
cancer in people associated with poor oral hygiene and 
the fact that attention to dental health by the general 
population reduces the risk of oral cancer, has led to 
postulate a possible correlation between OSCC and oral 
microbial flora [30]. The presence of abundant 
accumulations of plaque above and below gingival and 
of periodontal disease conditions have in fact been 
correlated to the onset of pancreatic malignant 
neoplasms of the lung and even renal [31], 
hypothesizing a possible interaction with mutagen 
between the polymicrobial supragingival plaque and 
saliva [32]. 
Ultimately, various hereditary conditions such as 
xeroderma pigmentosum, Fanconi's anemia, 
dyskeratosis congenita and Li Fraumeni syndrome can 
play a favoring role in the development of OSCC [33]. 
In recent years, thanks also to the development of new 
genomic analysis and sequencing technologies, various 
genetic alterations characteristic of OSCC have been 
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attributed, mainly related to the overexpression of 
oncogenes and/or the silencing of tumor suppressor 
genes. 
Using microarray-based gene expression analysis, 
Fialka F. et al noticed that 601 genes are differently 
regulated in cancerous tissue than adjacent contralateral 
mucosal controls. By comparing early-stage cancer 
samples with those from advanced disease, they 
measured the presence of 25 genes with important 
differences in terms of expression, in particular FMO2, 
CPA6, TNC, and SIAT1 genes were overexpressed in 
the early stages of the disease [34]. 
Chiang W.F. et al identified the mutation and 
overexpression of a gene - the epidermal growth factor 
receptor (EGFR) - in oral squamous cell carcinoma 
associated with the use of areca. 
Significant increases in EGFR copy number were found 
in OSCC compared to adjacent oral mucosa, suggesting 
that genomic amplification could be a genetic basis for 
EGFR pathway activation in areca-associated OSCC 
[35]. 
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According to the research conducted by Serefoglou Z. et 
al it has been evaluated that the presence of functional 
polymorphisms that influences the gene expression of 
the interleukins IL-4, -6, -8 and -10, as well as of the 
tumor necrosis factor-alpha (TNF -a), is strongly 
associated with an increased risk of OSCC [36]. 
It has also been assessed that the consumption of 
chewed tobacco induces TNF-a which, together with its 
receptors, is overexpressed in the OSCC. Single 
nucleotide polymorphisms (SNPs) in the TNF-a and TNF 
receptor genes can influence their expression and can 
be a determining factor for an increased susceptibility to 
OSCC related to smoked tobacco [37]. 
Coutinho-Camillo CM et al demonstrated, by analyzing 
by immunohistochemical investigations of 229 cases of 
OSCC, arranged in a tissue microarray, the possible 
involvement of proteins of the Bcl-2 family in the 
tumorigenesis of OSCC and suggest that the expression 
of molecules apoptosis could be used as a prognostic 
indicator for OSCC [38]. 
Recently, Chaudhary A. et al. have focused on matrix 
metalloproteinases (MMPs), which are enzymes that 
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degrade all components of the extracellular matrix, 
including collagen. They examined 362 patients with oral 
submucosal fibrosis (OSMF), head and neck injuries. 
They have concluded that the expression of the MMP-3 
genotype associated with the 5A alleles may play an 
important role in the susceptibility of patients to develop 
OSMF, head and squamous cell carcinoma of the neck 
[39]. 
 
1.2 Epidemiology of oral squamous cell 
carcinoma (OSCC) 
 
Squamous cell carcinoma (OSCC) is the most frequent 
malignant tumor of the oral cavity and oropharynx. 
Epidemiological data indicate that, among all malignant 
tumors, it ranks sixth in the world average as per 
incidence [40]. 
In Italy, the average incidence is about 8 new cases per 
year for every 100,000 inhabitants among men and 3 
new cases among women. The incidence rates are 
higher in the northern regions than in the central and 
southern ones.  
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In industrialized areas, in the Alpine valleys and 
especially in the north-east, oral cancer is widespread. 
The considerable variations in the regional incidence of 
oral cancer reflect differences related to local customs 
such as tobacco consumption and alcoholic beverages 
[41].  
Oral cancer mainly affects subjects around the fifth-sixth 
decade of life, but in recent years the incidence in 
subjects under the age of 60 has drastically increased 
[42]. 
Prognosis in OSCC depends on tumor, treatment and 
patient factors. It is generally accepted that the 
prognosis is better in early cancers, especially in well-
differentiated and non-metastatic ones: unfortunately, 
most OSCCs are diagnosed in an advanced stage of the 
disease. 
The neoplasm spreads by forming predominantly 
lymphatic metastases in the lymph nodes of the neck. 
Metastasis can occur, albeit more rarely, even at a 
distance, especially in the lungs. 
In recent decades, no improvement has been shown 
either in prognosis nor in therapy, so the differences in 
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the mortality rate between geographical areas and time 
periods could be attributed to variations in exposure to 
risk factors [43]. 
The average survival is 41% among men and 54% 
among women at 5-years survival rate [44]. 
Despite information and primary prevention programs 
throughout Europe, the analysis of mortality curves for 
oral and oropharyngeal cancer has shown stability in all 
countries for both men and women. 
Although extremely expensive and characterized by a 
great expenditure of energy, the therapy is generally not 
very effective in the medium to long term given that 80% 
of stage III and IV patients die in the first 5 years; 
metastases recur in about 50% of patients. 
Only if the cancer is diagnosed at an early stage, the 5-
year survival rate reaches about 80-90% and the cost of 
therapy in human terms is lower. 
For these reasons, early diagnosis plays a crucial role in 
improving the patient's prognosis. 
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1.3 Clinic and current therapies of squamous 
cell carcinoma 
 
Squamous cell carcinoma is characterized by an early 
infiltrative tendency and a greater spread through the 
lymphatic route than the hematogenous one. Lymph 
node infiltration is influenced by the site of the neoplasm, 
its size, tumor histotype, histological differentiation, the 
anatomical structure of the affected organ and its 
lymphatic network, the relationships with nearby 
















Fig.2.  Lymph node infiltration 
 
The presence of a solitary lump, associated with fixation 
in the periwound tissue, an indolent ulcer or a white or 
red lesion that has persisted for more than 3 weeks, the 
presence of an alveolus that does not evolve towards 
spontaneous healing or changes in sensitivity not 
referable to a specific cause can represent the initial 
manifestations and alarm bells connected to the onset of 
OSCC. 
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Visual inspection is the critical moment in the formulation 
of the diagnostic suspicion throughout inspection and 
palpation of the oral cavity and - possibly - fibroscopy of 
the VADS. 
The clinical appearance of the carcinoma can be 
exophytic, endophytic (nodular or infiltrating), ulcerative 
with thickened edges or mixed exophytic-ulcerative [46]. 
Lymphatic diffusion is assessed through a palpatory 
clinical examination of the cervical-facial lymph node 
stations followed by imaging techniques (ultrasound, CT, 
MRI). 
Clinical staging uses the TNM classification system of 
the International Union against Cancer (UICC) - tumor 
size (T), lymph node metastases (N) and distant 
metastases (M) which allows a correlation between 
neoplastic characteristics, the type of treatment and the 
survival rate [47]. 
However, the definitive diagnosis is histological: 
squamous cell carcinoma arises in the context of a 
dysplastic epithelium. It is characterized by nodules or 
cords of malignant epithelial cells which invade the 
spaces beyond the basement membrane [48]. 
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Treatment of oral and oropharyngeal cancer uses the 
combination of demolition and reconstructive surgery, 
chemotherapy and radiotherapy. 
Surgical therapy involves the resection of the primary 
tumor possibly associated with the removal of 
laterocervical lymphatic metastases and currently 
represents the most effective therapeutic response, 
especially if well-coordinated in the context of 
multimodal protocols. 
Even though maxillofacial resective surgery represents 
an extremely invasive procedure due to the mutilation 
imposed on the patient by the surgical act, it still appears 
to be as the therapy of choice in the case of early 
injuries and in more advanced stages – both associated 
with or without lymph node removal [49]. 
Radiation therapy is often used as an adjuvant form of 
surgery, but in some inoperable cases it is considered 
the primary therapy. Fractionation is required to optimize 
the effect of the therapy on neoplastic tissue, given that 
ionizing radiation has a greater effectiveness of on the 
duplicating cells. Today it is suggested to administer a 
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dose of 2.0 Gy/fraction, for a total of 1000cGy/week, 
divided into one dose per day for five days. 
The radio-treated patient in the cervicofacial area is 
subject to a greater risk of disabling complications, such 
as osteoradionecrosis of the maxillary bones, especially 
mandibular, xerostomia and hyposcialia, superinfections, 
painful ulcers and erosions, scarring and trismus, decay 
of the residual dentition and periodontium [50]. 
Chemotherapy has been used with various purposes, 
ranging from palliative treatment to therapeutic treatment 
and radiotherapy completion process. Cisplatin is still 
considered as the drug of choicetoday. [51] 
 
1.4 Other variants of oral carcinoma: 
verrucous carcinoma 
 
In the context of the oral district, a variant of the OSCC 
that deserves to be considered concerns verrucous 
carcinoma (OVC), first described and defined as OVC in 
1948 by Lauren V. Ackermann (also known as 
"Ackermann's tumor" or "Ackermann's warty carcinoma") 
[52]. 
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This type of neoplasm is a low-grade and well-
differentiated clinical variant with a warty appearance of 
OSCC, which from an epidemiological point of view 
accounts for about 2-12% of all oral carcinomas, in 
association with a rate of 5-year survival averaged 50% 
[53]. 
As for the clinical features, the OVC is a malignant tumor 
characterized by slow exophytic growth, which generally 
appears as a warty growth, similar to cauliflower and a 
mammary surface [54]. 
In histological terms, this variant mouse exhibits a 
microscopic characteristic typical of the "push boundary" 
(both light and electronics) with an invasive local pattern 
and rare regional and distant metastases [55]. 
From the etiological point of view, the OVC is associated 
with multiple factors, taking the form of a pathology of 
extreme complexity [56]. 
The main association factors certainly include the 
consumption of alcohol, smoking, the habit of chewing 
areca nuts and alterations of the oral microbiota which 
individually or synergistically contribute to oral 
carcinogenesis [57]. 
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Other causative factors investigated in the genesis of 
this neoplasm have included: incongruous prostheses, 
pre-existing lesions and scars and chronic inflammation 
associated with autoimmune conditions involving the 
oral cavity. In some cases, as with OSCC, it can 
originate in apparently healthy oral mucosal sites or 
arise in the context of potentially malignant disorders, 
including oral warty leukoplakia, oral lichen planus, oral 
submucosal fibrosis (OSF), odontogenic keratocysts 
[58]. 
Among the various causative agents of OVC, the 
pathogenic role of the human papillomavirus (HPV) is 
widely debated, as shown by numerous works in 
literature which often lead to very conflicting results. 
Researchers found the presence of HPV DNA in 12 
(48%) out of 25 OVC patients. In particular, the 
identification of HPV 18 DNA in 40% of OVCs revealed, 
according to this study, an association between HPV 
and OVC although the potential etiological and 
prognostic significance of HPV in OVC deserves further 
exploration [59]. Conversely, other scholars have argued 
that the role of HPV may only be occasional as there is 
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no verified correlation between OVC and HPV. This 
working group examined the role of HPV in association 
with OVC development, analyzing 39 OSCC, 8 OVC and 
9 normal mucosal samples. In this study, no correlation 
was established between HPV and OVC because all the 
tested samples were negative for HPV [60]. Evidently, 
further studies will be needed to investigate the real role 
of HPV in the context of this neoplasm in association 
with the use of highly sensitive molecular biology 
techniques in order to obtain a greater understanding of 
the subject. 
 
In reference to the clinical aspects, OVC often originates 
in the context of the buccal mucosa, in the tongue, lips, 
gum, alveolar ridge and floor of the mouth [61], showing 
a predilection for elderly males, especially those over the 
age of sixty [62]. Its prevalent clinical manifestations are 
represented by an exophytic development in association 
with a papillary aspect. Due to its slow growth and the 
prevailing tendency to local aggression leading to rare 
regional or distant metastases, OVC has a relatively 
good prognosis [63]. Based on clinical manifestations 
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and prognosis, a research group divided OVC into three 
types: exogenous type, cystoid type, and infiltrative type. 
The exogenous type of OVC is characterized by 
exophytic growth, a cauliflower-like warty lesion, and 
slow tumor growth. However, the other two types of 
OVC grow rapidly, forming highly thickened keratoses, 
associated with a poor prognosis compared to the 




Fig.3. Oral verrucous carcinoma of alveolar ridge. 
 
Regarding histological characteristics, OVC epithelial 
cells are well differentiated, having a weak cellular 
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atypia. The squamous epithelium of the OVC shows a 
highly proliferative papillary appearance and a marked 
keratosis. The highly proliferative epithelial pegs 
showswelling with blunt drop-shaped tips. All epithelial 
pegs are infiltrated into the connective tissue to the 
same depth, forming the thrust contours [65]. Many 
lymphocytes and plasma cells are also infiltrated into the 
connective tissue where cancer cells can degenerate or 
be ingested by phagocytic cells, resulting in the 
destruction of the carcinoma cells. Between the 
squamous epithelium and connective tissue, most of the 
components of the epithelial basement membrane (BM) 
of OVC remain intact. 
 
Since its first discovery, few other subsequent works 
have focused on studying this clinical variant of oral 
cancer. Although subsequent research into the 
diagnosis and treatment of OVC was largely initiated at 
the beginning of this century [66], the progress of 
research is still far from being completely satisfactory. 
Even today, in some cases, the differentiation of OVC 
from OSCC is sometimes difficult by simply observing 
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the clinical and pathological characteristics, while in 
someother casesit has been possible to find a biological 
behavior of OVC similar to OSCC, in terms of tendency 
to invasion local [67]. The precise identification of this 
subtype of neoplasm – within the broader group of oral 
carcinomas - is therefore extremely important, with 
regard to their different molecular mechanisms and 
prognosis. 
 
1.5 Long Non-Coding RNA 
 
In recent years, the development of increasingly 
sophisticated high-throughput sequencing techniques 
has led to the discovery that only 2% of the human 
genome is associated with protein-coding genes and 
that the vast majority of the human genome is actively 
transcribed as non-coding RNA (ncRNA) (Wright and 
Bruford, 2011). 
Long Non-Coding RNAs (lncRNA) are a ncRNA class 
longer than 200 nucleotides which - until few years ago - 
were defined as "junk DNA" [68]. The literature provides 
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both various classification criteria and different types of 
definitions about this kind of molecules. Overall, these 
are obligated transcripts of RNA, that is "non-coding", 
therefore not associated with transcriptional units 
encoding known proteins and characterized by a 
relatively long sequence [69], arbitrarily defined to be 
greater than 200 nt, to make a distinction with respect to 
most other groups of small ncRNA transcripts, such as 
microRNA, tRNA, small nuclear RNA (snRNA), rRNA, 
small nucleolar RNA (snoRNA). This length has been 
defined both for practical implications and to provide a 
classification criterion during the common experimental 
procedures of RNA separation. 
The nucleotide sequence of lncRNA forms its primary 
structure, while, hydrogen bonds formed by the internal 
structure of RNA (including the Watson-Crick face, the 
Hoogsteen face and ribose) build its secondary structure 
which includes double helices, rings hairpin, bulges and 
pseudopods. 
Furthermore, thanks to their higher structural length, in 
comparison to other classes of ncRNA, lncRNAs can 
fold into more complex three-dimensional structures. It 
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has also been shown that these three-dimensional 
structures can determine specific interactions of 
lncRNAs with transcription factors and histones and 
other chromatin-modifying proteins. Chromatin-
modifying proteins can affect the expression level of a 
broad spectrum of genes [70]. 
Most lncRNAs are synthesized by RNA polymerase II 
thanks to an intrinsic greater synthesis activity, while 
RNAPoli I and III are generally limited to the transcription 
of shorter RNA transcripts. The primary transcript then 
undergoes a process of capping at 5', polyadenylation at 
3' and splicing to be functional and this process allows 
the stabilization of the transcripts allowing the 
preservation of their functional role. 
These molecules share many of the biological 
characteristics of mRNAs and although they have little or 
no coding potential, some recent studies have 
suggested a possible ribosomal involvement in 
producing small polypeptides [71]. 
Regarding the transcriptional profile, lncRNAs are 
generally expressed at lower levels than transcripts 
encoding known proteins. Compared to the latter, their 
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expression pattern is more specific for the definition both 
of the developmental stage and of the cell type [72]. 
Their primary structure and the complex secondary 
structures of lncRNAs allow them to interact specifically 
with DNA, RNA and proteins. Since lncRNAs are 
localized both in the nucleus and in the cytosol, they can 
act at virtually any level of gene expression by 
modulating their expression through a series of 
mechanisms at the epigenetic, transcriptional and post-
transcriptional level [73]. 
LncRNAs can be divided into several functional 
categories based on the site of action and on the level of 
gene expression, thus being based on their intrinsic 
characteristics: (1) according to their position in the 
context of the genome (intergenic and intronic lncRNA, 
lncRNA sense and antisense), (2) as a function of their 
effects on DNA sequences (cis-lncRNA, trans-lncRNA). 
(3) as a function of their regulatory mechanism 
(transcriptional, post-transcriptional or other functioning 
mechanisms), (4) as a function of their possible targeting 
action [74]. 
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Nuclear lncRNAs can be subdivided into cis-acting RNA, 
which work in close proximity to their transcription sites, 
and trans-acting RNAs that operate in distant loci. Both 
cis and trans-acting lncRNAs can activate or repress 
transcriptional phenomena through the recruitment of 
chromatin remodelers and modifiers, thus changing the 
chromatin status of a particular locus or even of an 
entire chromosome (Figure 1A) [75]. 
Nuclear lncRNAs are also able to induce or prevent the 
transcriptional mechanism, interacting with transcription 
factors, directly affecting the transcriptional output of a 
region (Figure 1B). Among these, Enhancer RNA 
(eRNA), are encoded by extragenic regions and promote 
the transcription of surrounding genes [76]. 
Participating also in post-transcriptional coregulation 
mechanisms at nuclear level, lncRNAs can indirectly 
interact in various steps with splicing processes or 
directly with nascent mRNAs to guide them towards 
particular splicing events. (Figure 1C) [77]. 
Depending on their regulatory activity and modeling of 
the subnuclear architecture, it has been observed that 
some lncRNAs can regulate the chromosomal cycle, 
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inducing or altering the interactions of the chromosomes 
themselves (Figure 1D) [78], while some other lncRNAs 
act as structural scaffolds in the formation and regulation 
of nuclear compartments under the form of speckles [79] 
and Polycomb bodies (Figure 1E) [80]. 
At the cytoplasmic level, lncRNAs influence the outcome 
of the translation process by acting in various ways. 
First, they can modulate the speed of the translational 
process by regulating the size of the polysome on an 
mRNA molecule (Figure 1F) or by controlling the internal 
ribosomal entry sites (IRES) [81] and  - secondly - they 
can regulate gene expression by reducing or stimulating 
mRNA decay (Figure 1G) [82]. A particular class of 
cytoplasmic lncRNAs, endogenous competitor RNAs 
(ceRNAs), regulate both translation and degradation 
rates of mRNAs, acting as molecular sponges for 
miRNAs, thus modulating the repressive activity of 
miRNAs on their mRNA targets (Figure 1H) [83]. 
Overall, lncRNAs exhibit remarkable functional flexibility 
and tightly regulated expression that give them 
enormous potential as fine tuners of cellular function and 
identity. Thanks to their versatility, IncRNAs are able to 
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control different aspects of cell development, from 
maintaining stem cells to both engagement and 
differentiation and we expect their biological role in a 
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Fig.4. Role of LncRNAs in mediation with modifiers of chromatin 
activity and transcription factors. 
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1.6 LncRNA and OSCC 
 
In the last decade the role of miRNAs in oral squamous 
cell carcinomas (OSCC) has been extensively studied. 
However, the functional role of lncRNAs in such tumors 
remains unclear. 
Due to their abundant presence in the human genome, 
and thanks to the characteristic of having tissue-specific 
expression patterns, the functional relevance of lncRNAs 
has assumed, in recent years, an increasingly greater 
value both in the study of physiological and pathological 
states, and in particular in the carcinogenic mechanism. 
In fact, these molecules play a fundamental role in gene 
regulation in relation to cell proliferation, survival, 
migration, and genomic stability. An alteration in the 
expression of these molecules has been associated at 
the beginning, at the progression of cancer, and at the 
spread on a local and systemic level [85]. 
In most cases, the presence of an altered expression 
profile of a given lncRNA is associated with an effect on 
the cancer phenotype. Such effect leads to an onco-
suppressive or oncogenic action, participating in various 
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cellular processes such as proliferation, differentiation, 
invasion tumor, and metastases. 
For these reasons, numerous studies have focused both 
on evaluation and comparison of the expression profiles 
of these non-coding molecules at the level of the normal 
oral mucosa with respect to the profiles found in frankly 
tumor tissue, even if the tumor suppressor or oncogenic 
function cannot be only determined on the basis of 
differential expression of lncRNAs in cancer. This also 
depends on predictions based on functional studies [86]. 
The main works found in the literature that discriminate 
the expression profile of lncRNA in OSCC, compared 
with the profiles of the healthy mucosa, have identified 
numerous transcripts associated with alterations in 
expression such as: HOTAIR; MALAT1 NEAT-1; HULC; 
MEG-3; UCA1 [87]. 
 
The HOTAIR transcript (Hox antisense intergenic RNA) 
represents perhaps one of the most studied lncRNA and 
associated with a wide variety of cancers, including 
breast, colorectal, nasopharyngeal and liver cancers 
[88]. HOTAIR was the first lncRNA found to associate 
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with PRC2 complexes, initiating the subsequent 
characterization of a large number of RNAs interacting 
with PRC2, later known as the PRC2 transcriptome. 
HOTAIR is also able to cooperate with the LSD1 
complex and can be regulated by various factors such 
as miR141, Ago2, c-Myc, TGF-β and small interfering 
RNAs (siRNAs), modulating various modifications at the 
epigenetic level [89]. 
Numerous studies have therefore focused on the 
evaluation of the expression profile of this LncRNA in the 
OSCC and almost all of them have discriminated against 
its overexpression [90],[91]. 
On the contrary, few studies have taken into 
consideration the expression of HOTAIR in dysplastic 
lesions and in any case did not reveal significant 
differences in expression [92]. 
Even if these studies are to be considered as preliminary 
not yet confirmedresults, they may suggest a possible 
variation towards the overexpression of this transcript 
contextually to the progression towards a malignant 
transformation. 
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The metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1), also called nuclear enriched 
abundant transcript 2 (NEAT2), is an intergenic lncRNA 
(LINCRNA) that maps to chromosome 11q13. MALAT1 
is involved in the proliferation, migration, invasion and 
apoptosis of tumor cells and in vitro, it has been found 
that MALAT1 acts as a sponge that downregulates miR-
125b and that, conversely, can lead to a significant 
upregulation of STAT3, thus favoring proliferation cell in 
colony formation assays. 
The expression of this lncRNA has been taken into 
consideration by numerous studies, which have found a 
significant overexpression especially with regard to 
TSCC[93], while no significant differences were found in 
terms of expression in the OSCC [90]. The only study 
addressing MALAT1 expression in dysplastic lesions 
found significant under-expression [92], suggesting that 
overexpression in OSCC, if demonstrated, could be 
related to progression from dysplasia to carcinoma. 
Other interesting studies have recently found, in a large 
cohort of patients, a significant overexpression of 
NEAT1 [94]. Something worth noticing is that other 
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studies have shown a downregulation of NEAT1 in the 
presence of dysplasia, suggesting a potential change in 
its expression during carcinogenesis [92]. 
The increased expression of lncRNA MEG3 has also 
been evaluated by other studies, and also in this case it 
has been consistently found in both OSCC and TSCC 
[95]. Several studies have then evaluated the expression 
profile of UCA1 with similar results in cancers of the oral 
cavity of multiple anatomic sites underlining how the 
overexpression of this lncRNA represented a significant 
cost in OSCC [96]. Other authors estimated that UCA1 
overexpression was not observable in the presence of 
dysplasia [92].  
Other studies on the expression profile of OSCC-related 
lncRNAs evaluated FTH1P3 overexpression, HIFCAR 
overexpression [97], and CCAT2 overexpression [98]. 
Colon cancer-associated CCAT1 and CCAT2 transcripts 
were also reported to behave differently in OSCC, 
finding that CCAT1 was overexpressed in only 27% of 
OSCC while CCAT2 was significantly overexpressed 
[98]. 
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PTENp1 was almost absent in OSCC compared to 
adjacent normal tissues [99], and therefore a significant 
underexpression found even in the presence of 
dysplasia, thus suggesting an early involvement of this 
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1.7 LncRNA expression and correlations with the 
anatomical site of origin 
 
Some of the lncRNAs associated with OSCC have 
shown well-defined roles in cancer development and 
progression, suggesting that these lncRNAs can be 
used as novel biomarkers and monitoring tools, as well 
as potential therapeutic targets in the treatment of 
OSCC, thanks to their specificity in terms of expression 
linked to the anatomical site of onset of the neoplasm. 
In fact, by comparing the expression levels within the 
larger chapter of squamous cell carcinomas of the head 
and neck district (HNSCC) it is possible to identify the 
presence of transcripts expressed in a different way 
between different types of cancer of different anatomical 
sites, thus suggesting that many lncRNA can serve as 
tissue-specific biomarkers [100].In this sense, for 
example, a characteristic overexpression of HOTAIR 
was evaluated in squamous cell carcinomas of the oral 
cavity (OSCC) that originated in the various oral 
anatomical sub-sites, but not at the lingual level. On the 
contrary, a reduced expression of the lncRNA GAS5 
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was demonstrated only in lingual squamous cell 
carcinomas (TSCC), which are not detectable in other 
tumors from other areas of the oral cavity. 
None of the above lncRNAs have been associated with 
a transcriptional alteration in the laryngeal SCC [86]. 
In a further study a different expression of lncRNA H19, 
AP5M1 and MALAT1 was evaluated in squamous cell 
carcinomas of the oral cavity OSCC, when compared 
with the levels of expression found in squamous cell 
carcinomas of the head and neck district (HNSCC), 
allowing to define a characteristic tissue-specific 
expression of lncRNAs and the fact that HNSCC fits into 
a heterogeneous group of tumors with different 
epigenetic alterations [90]. 
The non-coding transcript CCAT1 has been found being 
more OSCC expressed in heavy smokers or in tobacco 
chewing habituated patients. Furthermore, its greater 
expression was mainly documented in carcinomas 
originating in the buccal mucosa, in comparison to other 
oral anatomical sites. In this sense, the differential 
expression of CCAT1 found could be influenced both by 
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exposure and risk factors and by the anatomical site of 
onset of the neoplasm [101] 
 
1.8 LncRNA expression as a function of tumor 
characteristics and TNM staging 
 
More recently, a correlation was sought between the 
characteristics of tumor development in terms of size 
and locoregional involvement and lymph node 
metastatic spread with a possible aberrant expression of 
the main lncRNAs of oncological interest. 
Following this line of research, some studies reported 
that in the presence of nodal involvement the expression 
of HOTAIR, NEAT1 and UCA1 was significantly 
upregulated, while MEG3 was downregulated [102]. 
HOTAIR has been extensively investigated in numerous 
papers. The majority of them have supported a 
significant link between overexpression of this transcript 
and the presence of nodal metastases [102]. 
Such a trend associated with metastases has been 
related to increased tumor stem cell and metastasis due 
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to HOTAIR overexpression in oral cancer stem cells 
[91]. 
One author hypothesized that UCA1 overexpression 
promotes the metastatic but non-proliferative capacity of 
TSCC cells [103]. 
On the contrary, the link between lymph node 
involvement and the under-expression of MEG3 is not 
associated with a uniformity in the result [90]. 
Three studies reported conflicting results in MALAT1 
evaluation, overall suggesting that a significant 
overexpression in the presence of nodal involvement 
could only be found in TSCC 77 but further validation is 
required [90], [102]. 
Most TNM stage studies have compared lesions with 
stage I-II versus lesions with stage III-IV disease. When 
both TNM stage and nodal involvement were evaluated, 
some transcripts (CCAT2, EGFR, HOTTIP, PTENp1) 
appeared to be associated with tumor size rather than 
nodal involvement [99], [104], while others appeared to 
be related to nodal involvement but not tumor size 
(CEBPA-AS1, HAS2-AS1, MBL2-4: 3, TUG1, UCA1) 
[103], [105], [106]. 
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Finally, it should be noted that among the various 
evaluated transcripts in the literature regarding the 
possible association with both nodal involvement and 
tumor size, only LINC00152 [107], lnc-p23154 [108], and 
NKILA [109], showed a common significant alteration of 
the expression profile: over-expression in LINC00152 
and lnc-p23154, under-expression in NKILA. 
 
1.9 LncRNA and prognosis 
 
Some studies in the literature focused on the correlation 
between lncRNA expression and the 5-year prognosis. 
Some of these studies have assessed the survival rate 
in the absence of relapse. In most cases, when a 
significant link between lncRNA expression and 
prognosis was assessed, this expression was also 
related to the presence of nodal metastatic involvement. 
In a first study, it was revealed that H19 overexpression 
was significantly correlated with a poorer prognosis 
[110]. 
The estimated survival analysis was then evaluated in a 
cohort of OSCC patients and assessed that higher 
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HOTAIR expression was associated with poor survival 
[91]. 
HOTAIR was probably the most investigated transcript. 
Its prognostic role has been evaluated in multiple 
independent cohorts of OSCC patients. Despite the 
presence of conflicting results derived from studies 
exploring the association between HOTAIR expression 
and nodal involvement or tumor classification, almost all 
of them have found a negative impact of HOTAIR 
overexpression together with the association of this 
















2. EXPERIMENTAL PART 
 
2.1 Rationale for the study 
 
Several functional analyzes made on various cell lines 
and on animal models have shown that lncRNAs can be 
configured as key genomic regulators in a wide variety 
of biological pathways, including differentiation and 
development [113]. Based on these considerations, 
many studies have confirmed that a large number of 
lncRNAs are associated with an alteration of the 
expression profiles in various tumor types of different 
anatomical districts compared to the corresponding 
normal tissues. These lncRNAs are considered as key 
agents in the development, progression and possibly in 
the treatment of cancer [114]. 
Growing evidence has therefore suggested that 
lncRNAs may be configured as useful biomarkers in the 
diagnosis and prognosis of cancer with respect to 
protein-coding genes. This is possible thanks to 
lncRNAs specificity expression related to cell type, 
tissue of origin, and disease status, in relation to genes 
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encoding proteins. Moreover, the study of the 
expression profile could represent an indicator of the 
neoplastic state [115], [116]. 
The aim of the work is - in this sense - to carry out an 
observational retrospective study through the evaluation 
of histological and molecular biology analysis about the 
possible correlation between the expression profile of a 
lncRNA series in tissues frankly associated with 
metastatic and non-metastatic OSCC or in the OVC 
compared to control tissues, and compared to the 
general neoplastic behavior, in terms of local 
aggression, capacity for metastasis, preferential site of 
origin, and correlated prognosis. 
Through a careful analysis of the literature we tried to 
clarify the role played by the most cited lncRNAs, which 
are characteristics of different phases of the 
pathogenetic process of squamous cell carcinoma, so as 
to identify reliable biomarkers to better characterize the 
neoplastic staging. 
At the moment the staging is exclusively clinical and 
radiographic according to the TNM system, which does 
not often allow an objective forecast of the local or 
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systemic behavior of the tumor and does not provide any 
information, nor on the prognosis nor on the usefulness 
or otherwise of a certain surgical or radio-
chemotherapeutic approach. 
Despite public awareness campaigns carried out by 
scientific societies and government bodies in recent 
decades, the survival rate has remained unchanged, 
being around 50%. Therefore, refining the clinical study 
of this neoplasm using biomarkers able to predict local 
aggressive behavior, the ability to metastasize, the 
possibility of relapse, and the response to treatments it 
is considered as appropriate. 
The usefulness of the study is to provide planning tools 
to more personalized approaches to the patient, trying to 
be more incisive and targeted down to the molecular 
level in the eradication of the disease in affected patients 
or in a more conscious management of the quality of life 







2.2 Definition of the different research objectives 
 
• To carry out an analysis of the scientific literature 
aimed at identifying the most significant lncRNAs that 
may be associated with the different histological, clinical, 
and possibly prognostic aspects of squamous cell 
carcinoma of the oral cavity. 
 
• To identify which lncRNAs are useful for a possible 
classification of neoplastic behavior in terms of local 
aggression, lymph node metastatic spread, probability of 
recurrence. 
 
• To collect clinical documentation and histological 
samples in paraffin from patients - under treatment at 
the Circolo Hospital - diagnosed with oral squamous cell 
carcinoma or verrucous carcinoma and to verify their 
five-years survival rate. 
 
• To perform molecular biology studies using real-time 
PRC to compare the differential expression profiles of 84 
lncRNA among samples of non-metastatic oral 
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squamous cell carcinomas (nmOSCC), metastatic oral 
squamous cell carcinomas (mOSCC), and oralverrucous 
carcinomas (OVC), in relation to the control of samples 
of healthy mucosa, with the aim of evaluating any 
differences. 
 
• To proceed with the statistical study of the data through 
a univariate analysis for the evaluation of variations in 
the expression profile of neoplastic tissues (K) compared 
to healthy tissues (CNT) for each of the three subgroups 
nmOSCC, mOSCC, OVC. 
 
• Perform a multivariate analysis to discriminate the 
presence of a possible differential expression profile 
among the samples of the three subgroups (nmOSCC, 
mOSCC, OVC), through correlating the histological type 







3. MATERIALS AND METHODS 
 
 
3.1 Definition of population and examination groups 
 
 
The population to which the study is addressed is made 
up of patients with carcinoma of the oral cavity whose 
diagnosis was identified at the Oral Medicine clinic of the 
SC of Odontostomatology of the Circolo Hospital from 
2008 to 2013 for a total of 9 patients, divided as follow: 3 
non-metastatic oral squamous cell carcinomas 
nmOSCC, 3 metastatic oral squamous cell carcinomas 
mOSCC and 3 verrucous carcinomasOVC. The choice 
of the time period is dictated by the need to verify the 
survival rates, absence of disease or relapse after 5 
years. 
Further subdivisions of the study sample were then 
conducted in relation to the site of onset, the habit of 
smoking and alcohol or in relation to the absence of risk 
factors, survival or death, etc. All these aspects are 
influenced by the dysregulation of lncRNA. 
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In order to find the documentation stored in the medical 
record was therefore examined to find the following 
information on patients: sex, age, presence of risk 
factors, topographical site of the neoplasm, number of 
histological examinations carried out by the Pathological 
Anatomy Service of the Circolo Hospital, surgical 
treatment, chemoradiotherapy treatment, presence of 
cytopathic changes from HPV in the context of 
histological examination, relapse or absence of disease 
at 5 years, survival or exitus at 5 years, presence or 
absence of cervico-facial lymph node metastases, 
presence or absence of distant metastases, degree of 
neoplasm, stage of neoplasm at the time of diagnosis. 
An informed consent form was administered to those 
patients still attending our department for follow-up visits 
and to those who were not attending our clinic anymore 
but were available over the phone. The current study 







GENDER AGE' SMOKE TYPE LOCALIZATION STAGE GRADE 5-
YEAR 
SURV 
1 M 73 N/A nmOSCC TONGUE 2 2 0 
2 F 74 N/A OVC FLOOR 1 1 1 
3 F 55 EX mOSCC FLOOR-
VENTRE TON. 
3 2 0 
4 F 87 NO mOSCC FLOOR 4 2 1 
5 F 80 NO nmOSCC TONGUE 1 2 0 
6 F 52 EX nmOSCC TONGUE 1 2 0 
7 F 88 EX mOSCC TONGUE-
FLOOT 
4 2 0 
8 F 72 (5/die) OVC GUM-LIP INF 3 1 1 
9 M 85 (5/die) OVC CHEEK 2 1 1 
 
Tab.2.Differentiation and the groups under consideration based 
on the type of neoplasm, site of onset and lesional and 
prognostic characteristics. 
 
Once the clinical data collection has been carried out 
and the names of the patients eligible for the 
retrospective study and the histopathological report 
number indicated in the file have both been accurately 
identified, the Pathological Anatomy Service of the 
Circolo Hospital was requested to recover the 
corresponding stained slides in hematoxylin eosin. 
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3.2 Inclusion and exclusion criteria 
 
The study includes patients whose diagnostic and 
therapeutic path was carried out within the Circolo 
Hospital, so to avoid dispersion of data or difficulties in 
finding the missing information for the study. 
 
The samples stored in paraffin had to have sufficient 
material to be reused in order to proceed with molecular 
biology studies, while leaving the material in storage in 
the Pathological Anatomy archive. 
 
The normal control mucosa, adjacent to the neoplastic 
tissue and sampled at the time of tumor excision from 
the apparently normal tissue not connected to the 
excised cancer sample, had to be spaced at least 15mm 
from the latter, to exclude - at least partially - the 
possibility of a bias related to field carcinization. 
 
Patients who have undergone a diagnostic or 
therapeutic journey in facilities outside the Circolo 
Hospital were excluded from the data collection. 
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Samples that are insufficient for in-depth analysis or 
whose residual material would become insufficient for 
archival storage (exhaustion) were taken into 
consideration. 
 
Patients diagnosed with metastatic squamous cell 
carcinoma from other anatomical sites or other oral 
carcinomas other than those mentioned above are 
excluded. 
 
3.3 Methods of analysis in the laboratory 
 
 
The analysis on the expression profile of 84 lncRNA was 
conducted on histological samples from patients, which 
are stored in the Pathological Anatomy Service of the 
Circolo Hospital, using RT2 lncRNA PCR Array Kit for 
Human Cancer Pathway, Qiagen. 
 
The paraffin samples were processed using a 
mechanical sampling phase, thanks to an extraction 
template, which allowed the collection of both cancerous 
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tissue and considered healthy tissue, which has been 
used as control, being at least 15mm away from the 
neoplastic tissue. 
In particular, each sample from each patient has been 
cut in at least 4 sections, each section being10 µm thick, 
in association with a standardized extraction surface of 
250 mm2. 
All of these samples were then subjected to an 
elimination step of purified paraffin with 1ml xylene. 
Next step has then involved the extraction of total RNA 
and ncRNAs, throughout the use of the miRNeasy FFPE 
Kit, Qiagen. 
The quantification of the total nucleic acids and therefore 
of the total RNA was then conducted using a nanodrop. 
Before proceeding to the reverse transcription phaseit 
was decided to use a standardized quantity of RNA - 
equal to 110 nanograms - for each sample. 
The genomic DNA was then eliminated in order to 
remove any residual contamination in the RNA samples 
before reverse transcription, thus eliminating false 
positive signals. 
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The RNA was then subjected to the retro-transcriptional 
phase and converted to complementary DNA (cDNA) to 
increase its stability using the RT 2 First Strand kit for 
the synthesis of Qiagen cDNA. 
Subsequently, the pre-amplification phase was 
conducted using specific primers for the selection of the 
genes of interest with the RT2 lncRNA PreAMP Primer 
kit, Qiagen. 
A selective elimination of residual primers was executed 
before carrying out the PCR. 
Subsequent real-time PCR molecular biology 
investigations were then carried out using specific array 
assays, which were customized in Syber Green for the 
definition of the expression profile of 84 lncRNAs. These 
lncRNAs are known to be differentially expressed in 
numerous neoplasms of various anatomical districts, 
compared to normal tissue, using the RT 2 lncRNA PCR 
kit together with the RT2 SYBR Green Mastermix for 
qPCR, in association with a Quant Studio 3 Real Time 
digital instrument, Thermofisher Scientific. 
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Inside the plate there were also: control of reverse 
transcription, control of PCR, and control of genomic 
DNA contamination. 
During the comparison between control oral mucosa and 
neoplastic tissue, the following data have been studied 
and quantified: the statistically significant levels of 
modification in the expression profile of the lncRNA 
transcripts detectable in neoplastic tissues, compared to 
control ones, or in healthy mucosa. It has also been 
defined the presence of a“alteration of the expression 
profile of a lncRNA based on the expression related to 
the transcript normalized with the expression of a 
standard reference gene called housekeeping, 











3.4 Statistic analysis of the expression profile 
 
 
A relative quantification of the changes in expression 
level in multiple samples was conducted, related to an 
internal control, i.e. a reference gene, coamplified 




Tab.3.Reference gene coamplified together with the target of 
interest. 
 
The preparation of the data available, related to the nine 
selected cases, provided for the subdivision into three 
study groups, have been translated into 3 data folders 
(Classic metastatic, Classic non metastatic and 
Verrucous), in association with a file in.tsv format 
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containing the list of 84 lncRNAs investigated with 
descriptions of each well, plus the control wells. 
Each data folder contains the sheets defined as "results" 







After patient IDs and tissue IDs have been defined, they 
have been used for reading and classifying data for 
analysis. The study of the various amplification cycles 
envisaged that starting from the line containing the string 
defined "Well" and for 96 consecutive lines, the 
threshold cycle values (Ct) for healthy tissue samples 
(CNT) and associated samples were read cancer (K) 
referred to tissue ID. 
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The relative expression of the analyzed samples was 
then calculated by obtainingthe values of ∆C_t in the first 
























The term ∆∆C_t was then calculated, for the 
quantification of the relative variations of gene 
expression in tumor tissue compared to healthy tissue in 









The data related to the relative expression in the three 
subgroups, with respect to the healthy tissue of the 
same subject, have been evaluated by conducting an 
univariate analysis, that is, by individually evaluating the 
expression of individual lncRNAs in the neoplastic 
tissues and in the control tissues. A two-tailed 
parametric type test (Student's t) and a sample have 
been conducted for each examined subgroup or folder, 
in order to establish the probability that the mean 
variation is zero. This variation has been considered to 
be significantly non-zero for genes exhibiting p≤0.05 In 
the following phase, through a multivariate analysis, it 
has been decided to evaluate the trends in terms of 
lncRNA expression, directly comparing the three Classic 
metastatic, Classic non-metastatic, and Verrucosal 
groups, to evaluate a possible distancing and 
differentiation. The matrix containing the ∆∆C_t of all 
patients has been scaled and centered in order to avoid 
bias due to the differences between expression 
variations in the different single lncRNAs. A classifier 
has been then obtained by means of sPLS-DA (sparse 






Classic Metastatic (mOSCC) 
 
 
Position UniGene GenBank Symbol Description log2fold stdev p-value 
41 D05 Hs.433151 NR_024065 LINC00312 Non-proteincoding RNA 312 1.768 0,02 
56 E08 N/A  NR_102270 NAMA  Non-protein coding RNA, associated with MAP kinase 
pathway and growth arrest 
1.054 0,02 
65 F05 N/A ENST00000519282 PRNCR1 Prostate cancerassociated non-coding RNA 1 4.14 0,013 
80 G08 N/A ENST00000466156 TUSC7 Tumorsuppressor candidate 7 (non-proteincoding) 2.738 0,012 
83 G11 Hs.529901 NR_001564 XIST X  (inactive)-specific transcript (non-protein coding) 1.298 0,027 
 
Tab.4. Description of lncRNAs with p <0.005 associated with 
alteration of the expression profile in mOSCC, compared to 
healthy tissues of the same patient. 
 
 
Classic Non Metastatic (nmOSCC) 
 
 
Tab.5. Description of the lncRNAs with p <0.005 associated with 
alteration of the expression profile in nmOSCC, compared to 
healthy tissues of the same patient. 
Position UniGene GenBank Symbol Description log2fold stdev p-value 
22 B10 Hs.122718 NR_002785 GNAS-AS1 GNAS antisense RNA 1 3.621 0,022 
29 C05 Hs.197076 NR_003716 HOTAIR Hoxtranscriptantisense RNA (non-proteincoding) 2.285 0,048 
31 C07 N/A ENST00000421733 HOTTIP HOXA distal transcript antisense RNA 3.237 0,027 
45 D09 N/A ENST00000594200 LINC01233 Long intergenic non-proteincoding RNA 1233 3.075 0,014 
47 D11 N/A GU228577 LSINCT5 Long stress-induced non-coding transcript 5 3.061 0,023 
62 F02 N/A ENST00000519319 PCAT1 Prostate cancerassociatedtranscript 1 (non-proteincoding) 8.277 0,043 
65 F05 N/A ENST00000519282 PRNCR1 Prostate cancerassociated non-coding RNA 1 7.758 0,027 
74 G02 N/A AK024556 SPRY4-IT1 SPRY4 intronic transcript 1 (non-protein coding) 3.031 0.02 
76 G04 N/A ENST00000363312 TERC Telomerase RNA component 1.408 0,046 
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Verrucous carcinoma (OVC)   
 
 
Tab.6. Description of the lncRNAs with p <0.005 associated with 
alteration of the expression profile in the OVC, compared to 
healthy tissues of the same patient. 
 
From the results summarized in the tables, it is possible 
to highlight a significant considerably alteration of the 
expression profile of 5 lncRNA in the neoplastic tissue 
associated with the mOSCC sample, and in particular 
LINC00312, NAMA, PRNCR1, TUSC7, XIST X 
compared to control tissues. 
As regards the nmOSCC group, an alteration of the 
expression profile of: GNAS-AS1, HOTAIR, HOTTIP, 
LINC01233, LSINCT5, PCAT1, PRNCR1, SPRY4-IT1, 
TERC was found. 
Regarding the last OVC group, the following have been 
identified as regulated: AIRN, GACAT1, HIF1A-AS1. 
In most cases, the analysis showed a profile tending to 
overexpression.The use of multivariate analysis in 
Position UniGene GenBank Symbol Description log2fold stdev p-value 
4 A04 N/A  ENST00000601203 AIRN  Antisense of IGF2R non-protein coding RNA 3.481 0,009 
19 B07 N/A ENST00000419650 GACAT1 Gastric cancer associated transcript 1 (non-protein coding) -597 0,001 
26 C02 N/A ENST00000557544 HIF1A-AS1 HIF1A antisense RNA 1 [Source:HGNC Symbol;Acc:43014] 3.753 0,011 
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comparing the pattern of expression among groups: 
mOSCC, nmOSCC, OVC, associated with the use of 
both one and two components, found a good 









Graf.1. ROC curves of the three samples in multivariate one and 
two component analysis. You can see the evident separation of 
the expression profile in the one-component analysis and even 
































The two-component analysis made it possible to infer a 
ranking of distancing and maximization of variance, 
obtaining a good separation of the groups, with 45% of 
the total variance being described by the two main 
components. 
Therefore, the presence of this spacing in terms of 
variance has certainly shown significantly different 
profiles among the three groups, as figured out by the 
area under the ROC curve (AUC), which is always equal 
to 1 in the 2-component analysis. 
 
  
AUC 1 p-value AUC 2 p-value 
CLASSIC METASTATIC vs Other(s) 0.61 0.606 1 0.020 
CLASSIC NON METASTATIC vs 
Other(s) 
0.89 0.071 1 0.020 
VERRUCOSO vs Other(s) 1 0.020 1 0.020 
 
 
Tab.7. Values of the area under the ROC curve (AUC) in one 
and two-component analysis 
 
 
The subsequent analysis of the combined loadings for 
the two main components (√𝑃𝐶12 + 𝑃𝐶22) shows that 
we can focus on the 10 major combined loadings, 
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allowing us to define which is the most responsible 
lncRNA for the separation between the three groups. 
 
 
AIRN, PANDAR, PVT1, TUSC7, GACAT1, PRNCR1, LINC00312 
 
 
Graf.2. Graphic representation of the most represented 





The following table lists the lncRNAs which show the 10 
highest combined loadings and therefore the most 
associated in differentiating the expression profiles of 
these three types of oral neoplasms. 








































Position UniGene GenBank Symbol Description 
Combined 
loadings 
A04 N/A ENST00000601203 AIRN 
Antisense of IGF2R non-
protein coding RNA 
0.263 
E12 N/A NR_109836 PANDAR 
Promoter of CDKN1A 










G08 N/A ENST00000466156 TUSC7 
Tumor suppressor 
candidate 7 (non-protein 
coding) 
0.245 
B07 N/A ENST00000419650 GACAT1 
Gastric cancer associated 
transcript 1 (non-protein 
coding) 
0.237 
F05 N/A ENST00000519282 PRNCR1 
Prostate cancer associated 






Non-protein coding RNA 
312 
0.233 
C01 N/A NR_045680 HEIH 
Hepatocellular carcinoma 
up-regulated EZH2-
associated long non-coding 
RNA 
0.233 
E10 N/A NR_028272 NEAT1 
Nuclear paraspeckle 
assembly transcript 1 (non-
protein coding) 
0.232 
F12 N/A ENST00000455390 
RPS6KA2-
AS1 








OSCC is the second most common malignancy in the 
head and neck, alongside with nasopharyngeal cancer. 
Depending on anatomical causes, related to high 
vascularity, lymphatic distribution and frequent 
movement, OSCC is characterized by a high 
proliferation and early metastatic tendencies. Even 
advanced surgical treatment combined with neoadjuvant 
chemotherapy is associated with a 5-year survival rate 
that is still below than 50%. Therefore, it is deemed 
necessary to explore more effective therapeutic targets 
for this type of neoplasm. 
Recently, together with the most well-known biological 
and molecular factors associated with the OSCC 
genesis process, it has been widely demonstrated that 
even complex genetic, transcriptional, and epigenetic 
alterations along with their interaction can actually 
contribute to the tumorigenesis of OSCC [117]. 
Traditional diagnostic methods, such as biopsy, 
radiographic evaluations, and chest CT are partially 
inadequate to get an objective evaluation of the profile 
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and intrinsic behavior of the tumor, as well as its 
evolution. For this reasonit has been decided to move 
towards the search for specific and sensitive biomarkers 
for a deeper diagnosis of OSCC. 
Numerous alterations in molecular profiles have been 
observed in various human cancers compared to 
corresponding normal tissues and they have been then 
used as novel markers for cancer diagnosis and 
prognosis [118]. 
LncRNAs are recently emerging as a new promising 
biomarker for cancer diagnosis and prognosis thanks to 
the increasing efforts on the characterization of these 
molecules in various human cancers. Recent studies 
have also observed many alterations in the expression 
profile of lncRNA with implications in an oncogenic or 
oncosuppressive sense at the tumor level. 
Despite these previous investigations, the expression 
pattern and diagnostic role of lncRNA in OSCC remain 
unclear. 
For these reasons, in this study we investigated the 
expression profile of 84 lncRNA in oral cancer tissue 
samples (K), with both different histological features and 
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different behaviors, compared to the healthy control 
mucosa (CNT), by means of PCR RT molecular biology 
techniques. We then analyzed the data by univariate 
and multivariate analysis. The analysis of the lncRNA 
expression files in the metastatic, non-metastatic and 
OVC, OSCC samples and of the control samples, has 
allowed to detect characteristics and significant 
alterations between the groups under examination 
compared to the control tissue, as a first step towards 
identification of diagnostic biomarkers of lncRNA. 
A total of 17 lncRNAs were determined as lncRNAs 
expressed differentially for p values <0.05, within the 
three analyzed groups of neoplastic tissue, compared to 
control tissues. 
The following have been identified for the mOSCC 
group: LINC00312, NAMA, PRNCR1, TUSC7, XIST X, 
RN7SK. 
Regarding the nmOSCC group, a statistically significant 
alteration of the expression profile of: GNAS-AS1, 
HOTAIR, HOTTIP, LINC01233, LSINCT5, PCAT1, 
PRNCR1, SPRY4-IT1, TERC was found. 
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While regarding the last OVC group, the following were 
identified: AIRN, GACAT1, HIF1A-AS. 
We therefore tried to define which - among these and 
based on their expression profile - possible diagnostic 
biomarkers with possible tumor suppressor or oncogenic 
roles, in relation to the data relating to the stage of the 
disease, subgroup of the sample site of onset. 
After a careful search in the literature, we found that 
several lncRNAs identified in our study were reported to 
be involved in models of carcinogenesis and tumor 
evolution characteristic of other malignant neoplasms of 
other anatomical districts. 
In the group of mOSCC samples, which were associated 
with the presence of metastases to the locoregional 
lymph nodes, an overexpression of LINC00312 (Non-
protein coding RNA 312) (p 0.002) was measured 
compared to the control tissue, which has also been 
found in studies relating to adenopulmonary carcinoma 
(ADC). In that anatomical district the expression level of 
LINC00312 was measured in 124 ADC-coupled tumor 
tissues and in adjacent non-tumor lung tissues using 
qRT-PCR. In this case an overexpression of LINC00312 
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has also been found in patients with ADC metastases 
compared to patients without metastases (p <0.0001). 
Clinicopathological analysis revealed that high 
LINC00312 expression was associated with lymph node 
metastases (p <0.001), distant metastasis (p <0.001), 
tumor node metastasis stage (TNM) [119]. 
Other research has revealed that the overexpression of 
LINC00312 inhibits proliferation by arresting the 
progression of the cell cycle from G1 to S phase, 
however, increasing cell motility and invasion, both in 
vitro and in vivo via the H-ras / pc pathways. -Raf and 
JNK2 / AP-1 / MMP1 in cells from nasopharyngeal 
carcinoma (NPC) samples [120]. 
An alteration of the NAMA lncRNA expression profile 
has been evaluated, (p 0.002) also found in other 
studies, in particular with regard to thyroid neoplastic 
tissues of papillary carcinoma, more associated with 
aggressive behaviors [121]. 
PRNCR1 found on 8q24 has been associated with 
alterations in its expression profile in aggressive forms of 
breast cancer, withsimilar overexpression levels to those 
found in the mOSCC group (P 0.013). A study has 
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recently conducted, also in this case, an analysis by 
quantitative reaction in real time of the polymerase chain 
(RT-qPCR) used to measure the expression levels of 
selected lncRNAs in tumor tissues obtained from 50 
tumor patients breast (BC) versus normal adjacent 
tissues (NAT) and 50 clinically healthy normal tissues. 
From the results of this analysis it was found that, given 
the increased expression of PRNCR1, this could act as 
an oncogene in BC and a greater expression of this 
lncRNA was in general associated with worse outcomes 
in BC women [122]. 
Growing evidence has indicated that TUSC7 lncRNA 
may be configured as a novel cancer-suppressing gene 
in various cancers. However, it is urgent to clarify the 
function of TUSC7 in oral carcinoma, since, in contrast 
to most other studies investigating this lncRNA, we 
found a high level of expression compared to healthy 
tissue (p 0.012). In most of the research, TUSC7 has 
instead been evaluated as significantly decreased in the 
tissues and cell lines of various types of cancer. 
Furthermore, a study evaluated a correlation between 
low TUSC7 expression with advanced clinical grades 
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and poorer overall survival in pancreatic carcinomas. 
TUSC7 would repress cell proliferation, migration, 
invasion, epithelial-mesenchymal transition and 
stemness while facilitating cellular apoptosis of 
pancreatic carcinoma cells [123]. 
XIST X lncRNA expression has been associated with 
altered profiles - using quantitative real-time PCR (qRT-
PCR) assays - in numerous studies investigating CRC 
colorectal cancer cell lines. Among all the works that 
have been carried out, one among all analyzed 196 
clinical samples, evaluating the possible correlations 
between XIST expression and the clinical-pathological 
characteristics of the CRC.  XIST lncRNA, as in our 
mOSCC unit (p 0.027), was measured as upregulated in 
cell lines and CRC tissues (p <0.05) compared to control 
tissues. Statistical analysis found that elevated XIST 
expression was correlated with larger tumor size, lymph 
node metastases, and higher staging. Furthermore, 
according to this study, an increased expression of XIST 
could predict poor progression-free survival (PFS) and 
poor overall survival (OS) of patients with CRC [124]. 
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In reference to the nmOSCC group, therefore not 
associated with lymph node metastases and with 
theoretically more favorable clinical characteristics, other 
lncRNAs emerged with a very well differentiated overall 
expression pattern compared to the mOSCC and OVC 
groups, as highlighted by the two-component 
multivariate analysis. The obtained results, in terms of 
expression profile, have sometimes differed from those 
found in the literature, probably due to the fact that all 
the samples belonging to the group were early 
neoplastic stages and all with lingual onset. 
With reference to this group, for example, a differential 
expression of GNAS-AS1 in neoplastic tissue compared 
to control tissue (p 0.022) was evaluated in our study, 
which has also been found in works on non-small cell 
lung cancer (NSCLC), where its overexpression was 
correlated with both the promotion of M2 polarization of 
macrophages and the progression of neoplastic cells. In 
the NSCLC clinical specimens investigated by this 
research, the expression level of GNAS-AS1 was 
significantly increased in tumor tissues compared to 
adjacent normal tissues, as found in our sample for 
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OSCC. The hyperexperience for this neoplasm was also 
indicative of lymph node metastases, moreover GNAS-
AS1 expression was higher than in non-metastatic cases 
[125]. 
Long non-coding HOX transcript antisense RNA 
(HOTAIR lncRNA) is overexpressed in many types of 
human cancers and has frequently been related to 
clinical stage and lymph node metastasis in oral 
squamous cell carcinoma (OSCC). 
Overexpression of HOTAIR can promote carcinogenesis 
and metastasis in many cancers, including breast, 
colorectal, and ovarian cancers. The proliferation and 
invasion capacity of tumor cells can be effectively 
suppressed by voluntary suppression of this drawback 
[126]. 
It has been widely reported that HOTAIR is found to be 
significantly upregulated in primary breast cancer and 
associated with metastases, compared to normal control 
breast tissues. Indeed, some studies have proposed that 
HOTAIR promotes the progression and metastasis of 
breast cancer cells by combining agRNA (siRNA 
antigen) to silence the metastatic inhibition gene [127]. 
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HOTAIR's RNA interference would not only reduce the 
invasion and metastasis of liver cancer cells but, 
according to some studies, it would also participate in 
the development and promotion of cisplatin and 
doxorubicin susceptibility conditions [128]. Recent 
studies have also shown that HOTAIR inhibits 
intercellular adhesion proteins (including JAM2, 
PCDH10 and PCDHB5) and can promote pro-metastatic 
genes (such as SNAIL and LAMB3) in breast cancer. 
HOTAIR expression has also increased in oral 
squamous cell carcinoma (OSCC) and has been 
associated with metastases, stages and histological 
differentiation. Furthermore, HOTAIR overexpression 
has often been reported to have poor prognosis in 
patients with OSCC. 
The relative expression of HOTAIR is correlated with 
tumor size and clinical stage. Furthermore, a significant 
negative correlation was determined between HOTAIR 
and E-cadherin expression levels in OSCC tissues and 
cells: HOTAIR would be involved in the regulation of E-
cadherin by binding to EZH2 and H3K27me3 on the E-
cadherin gene promoter. These results suggest that 
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HOTAIR expression could be one of the critical targets 
in progression and metastasis, as well as an indicator of 
poor survival in OSCC [85]. For our study, the presence 
of HOTAIR overexpression, which is prevalent in the 
group of carcinomas not associated with metastases, 
could be related to the fact that all the neoplasms of this 
group were in the early stages and perhaps in the 
prodromal stages to the subsequent lymph node spread. 
Another explanation for the overexpression of this 
lncRNA within the group of non-metastatic carcinomas 
nmOSCC, could lie in the fact that all the tumors in the 
sample are lingual carcinomas. However, in line with 
what has been reported in the literature, the 
overexpression of HOTAIR was accompanied by a 
poorer prognosis, regardless of the metastatic spread 
and with the same treatment. 
In the nmOSCC group, a statistically significant (p 0.027) 
alteration of HOTTIP expression was then evaluated, 
identified as upregulated also in gastric cancer tissues 
compared to the levels of the non-tumor counterpart. 
Furthermore, HOTTIP expression levels were 
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associated with poor differentiation, advanced TNM 
stages, and lymph node metastases [129]. 
Still with reference to this lncRNA, the relationship 
between HOTTIP expression and overall or disease-free 
survival in 90 patients with pancreatic carcinoma, after 
radical resection, was also analyzed. Patients with 
higher HOTTIP expression had shorter disease-free 
survival and overall survival than those with lower 
expression [130]. 
LSINCT5 (long stress-induced non-coding transcript 5) 
is dramatically upregulated in breast and ovarian cancer 
and is closely involved in cell proliferation. The aberrant 
expression of LSINCT5 was detected in gastrointestinal 
cancer with respect to adjacent normal tissue samples 
or with respect to cell lines, using quantitative reverse 
transcription PCR (RT-qPCR). Numerous studies have 
also focused on the potential relationship between 
LSINCT5 tumor levels and the clinical pathological 
features of gastrointestinal cancer, noting that the 
increased expression of LSINCT5 was related to a larger 
tumor size, deeper tumor depth, and an advanced 
clinical stage [131]. 
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Prostate cancer-associated transcript 1 (PCAT1) has 
been reported as originally identified as a prostate 
cancer overexpression lncRNA by RNA sequencing and 
would contribute to cancer progression through the 
regulation of a number of target genes. 
Alterations in its expression profile are accompanied by 
the development of a variety of human cancers, 
including esophageal squamous cell carcinoma (ESCC), 
lung cancer and hepatocellular carcinoma, acting as a 
biomarker of poor prognosis. High expression of PCAT1 
was observed in ESCC tissues and is associated with 
poor survival. 
Preliminary studies have then found that the 
overexpression of PCAT1 in ESCC tissues and cell lines 
was associated with an increase in the proliferation 
activity of tumor cells, by means of a sponging 
mechanism against miR-326. Specifically, PCAT1 would 
function as a ceRNA, sequences with regulatory 
functions of miRNA activity through base-pairing 
interactions. By means of a sponge coupling towards 
miR-326, its action as a tumor suppressor and 
interaction with KRAS would be determined with 
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variations in the regulation of AKT and ERK signaling 
pathways [132]. 
From the results of our analysis, this lncRNA was 
strongly overexpressed in the OSCC samples, as also 
found in the literature with regard to tissues associated 
with esophageal squamous cell carcinomas (ESCC). In 
this sense, given the proximity of the causal factors, 
further molecular biology studies to evaluate a possible 
common pathway of carcinogenic development 
associated with the same alterations. 
Growing evidence has suggested that non-coding 
prostate cancer RNA 1 (PRNCR1) may participate in the 
pathogenesis of non-small cell lung cancer (NSCLC). In 
fact, numerous studies have found PRNCR1 as 
upregulated in tissues and cell lines of NSCLC. In this 
case a specific interaction was also found with a 
molecule not encoded by miR-126-5p, being a tumor 
suppressor in multiple tumors of multiple anatomical 
districts and regulator the mechanisms of proliferation 
and invasion of tumor cells [133]. 
SPRY4-IT1 (intron transcript SPRY4 1), is a lncRNA 
derived from an intron within the SPRY4 gene, identified 
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as responsible for the development of multiple tumors. 
Specifically, in various studies, an alteration of the 
expression profile in gastric cancer samples was 
measured in a negative sense compared to the control 
tissues, allowing this molecule to associate with tumor 
suppressor activity. The reduced expression of this 
lncRNA, in fact, was associated with larger tumor size, 
advanced pathological stage, greater depth of invasion 
and lymphatic metastases and in general, patients with 
lower expression of SPRY4-IT1 were associated with a 
relatively poor prognosis. DNA methylation may be a key 
factor in controlling SPRY4-IT1 expression. 
Furthermore, SPRY4-IT1 would contribute to the 
development of gastric cancer cell metastases in part 
through the regulation of the epithelial-mesenchymal 
transition process (EMT) [134]. 
The presence of a SPRY4-IT1 overexpression, within 
the nmOSCC sample examined in our study, could be 
associated with the presence of regulatory mechanisms 
inhibiting cancer development, motivating the absence 
of a neoplastic behavioral profile aimed at metastasis 
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and correlating with the small lesion size and low 
staging. 
Ultimately, the overall expression profile highlighted as 
significant in the OVC group was on the whole well 
differentiated from the profile that emerged in the other 
two groups (mOSCC and nmOSCC). In the event that a 
constant alteration of the expression profile was 
ascertained in this histological subtype of oral cancer, its 
early definition in the biopsy phase of early neoplastic 
stages could have important implications on both the 
type of treatment and therapeutic approach in general. 
AIRN lncRNA has been investigated in 2 studies in the 
literature for its possible protective and restorative role 
against podocytes in relation to lesions induced by 
diabetic nephropathy by binding to Igf2bp2. While 
certainly falling into different areas and not associated 
with carcinogenesis, the overexpression of this lncRNA 
still facilitates cellular repair pathways and the vitality of 
podocytes, protecting them from apoptosis [135]. 
In our study, AIRN overexpression was found in the 
OVC group (p 0.009), therefore not statistically 
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associated with metastases and a generally better 
prognosis. 
The overexpression of GACAT1 has been evaluated in 
numerous studies referring to various anatomical 
districts, and associated with the promotion, 
proliferation, invasion and migration of neoplastic cells, 
specifically with regard to gastric carcinoma (GC). It was 
in fact confirmed that the lncRNA GACAT1 was 
upregulated, in a comparison study among 57 tissue 
samples GC tissues and cellular samples, also revealing 
that the knockdown of GACAT1 significantly suppressed 
the proliferation, invasion and migration of cells GC. The 
results of this study suggested that GACAT1 may act as 
an oncogene in GC and its overexpression may 
contribute to tumorigenesis and neoplastic progression 
[136]. 
The results that can be deduced from the quantification 
of this lncRNA in the OVC group, by investigation with 
RT PCR, express, in this group, hypoexpression values 
compared to the control tissue. This reduced expression 
could explain the behavior of this type of neoplasm, 
characterized by local aggression but at the same time 
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characterized by a low tendency to metastasize and to 
be able to relate and differentiate it from the expression 
profile and behavior of the OSCC. 
Long non-coding RNA (lncRNA) HIF1A-AS1 has been 
identified as capable of playing important regulatory 
roles in cancer biology, and its upregulation has been 
measured in several cancers such as glioblastoma, 
breast cancer, in a number of renal tumors, as well as in 
non-small cell lung cancer (NSCLC), through the 
interaction between the HIF1A-AS1 complex and 
apoptotic proteins, playing a key role in proliferation and 
apoptosis [137]. 
 
With reference to our study, the limit linked to the use of 
"apparently" healthy control samples at a standardized 
distance of 1.5 mm - which could be affected by field 
carcinization phenomena - certainly deserves to be 
mentioned. 
Secondly, it would be necessary to both introduce and 
use more specific test kits for squamous cell carcinomas 
of the head and neck area, which can effectively 
evaluate any pathways of alteration of the common 
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expression profile among the various neoplasms. On the 
basis of the data obtained, and in function of the 
differential expression in the various subgroups 
analyzed, it has been possible to infer the presence of 
characterizing profiles.  
Any future studies could further enrich and refine the 
mapping and the understanding of the altered 
expression profile of these feared neoplasms.The 
possible analysis of the expression profile of these 
lncRNAs in early diagnostic phases of an incisional 
biopsy type, in comparison with the expression profile of 
the tissues of a possible surgical piece, could provide 
clinical and therapeutic indications that could be 














Although treatment options for OSCC patients have 
improved in recent decades, the overall survival rate is 
still low, underscoring the importance of expanding 
research into new treatment options. We have turned 
our attention to the differential study of the expression 
profile of some possible tumor biomarkers between 
different subtypes of oral malignant neoplasms, 
associated with different behaviours, compared to 
healthy control tissues, to allow possible correlations on 
a diagnostic and possibly clinical level. The processing 
of the data emerging from the molecular biology analysis 
with RT PCR, in multivariate analysis with two-
component variance maximization, demonstrated a wide 
variety of profiles between the samples under 
examination (mOSCC, nmOSCC, OVC) and - more 
generally - each group is characterized by the 
dysregulation of several lncRNAs. 
In the group of OSCC associated with metastases, the 
lncRNAs LINC00312, PRNCR1, XIST X, could 
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represent, given their characteristic oncogenic action 
found in numerous other neoplasms, possible early 
indicators of an evolution in a metastatic sense, with 
possible implications in terms of staging. 
As regards the group of OSCCs not associated with 
metastases, lncRNA HOTAIR, PCAT1, SPRY4-IT1 were 
found as possible biomarkers. 
The two HOTAIR lncRNAs, PCAT1 have emerged as 
important oncogenes remarkably expressed in several 
squamous tumoral cells of the head and neck district 
(HNSCC). They could also be configured as prognostic 
indicators at the oral level, even in cases not necessarily 
associated with metastatic spread, as demonstrated in 
our study. 
SPRY4-IT1 lncRNA, overexpressed in the group of oral 
cancer not associated with metastatic spread, has been 
studied in the gastroenterological field for its onco-
suppressive action against gastric cancer. Reduced 
expression of this lncRNA, in fact, has been associated 
with larger tumoral size, advanced disease stage, 
greater depth of invasion and lymphatic metastases. 
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Ultimately, in the OVC group, a reduced expression of 
GACAT1 was measured, which could significantly 
explain the reduced proliferation, invasion, and cell 
migration, all of them being characteristics of this 
histotype. 
All these results, in their totality, lead to a new world 
view of contemporary oncology, including the need to 
integrate the knowledge acquired in Proteomics, 
Genomics, Transcriptomics and Metabolomics to 
epigenetic events, for which the main characters are 
long transcripts non-coding RNA (lncRNA). The 
interaction of different ncRNAs and lncRNAs in the 
different phases of cell biology could help in the 
development of new therapeutic and clinical aids if the 
regulatory dynamics of these transcripts were better 
defined. 
Further studies are therefore necessary for a more 
precise definition of the expression pattern of these 
neoplasms for a greater understanding of this labyrinth 
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